Ibrutinib 99.0%~101.0% Frontida
The world's first listed Btk inhibitor can not only effectively inhibit Btk targets, but also effectively act on ITK. Multi target synergy can effectively regulate the differentiation and number of car-t cells. It is the first-line treatment for patients with chronic lymphocytic leukemia (CLL).
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View